Literature DB >> 22633397

A new model of care for familial hypercholesterolaemia: what is the role of cardiology?

Gerald F Watts1, David R Sullivan, Frank M van Bockxmeer, Nicola Poplawski, Ian Hamilton-Craig, Peter M Clifton, Richard C O'Brien, Warrick Bishop, Peter M George, Christopher Semsarian, Andrew Tonkin.   

Abstract

Familial hypercholesterolaemia (FH) is a co-dominantly inherited disorder that causes marked elevation in plasma cholesterol and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but most remain undiagnosed and undertreated. To bridge this gap in coronary prevention the FH Australasia Network has developed a model of care for FH. We present the executive summary, with a commentary contrasting the recommendations with other international guidelines and highlighting the role of the cardiologist.
Copyright © 2012 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633397     DOI: 10.1016/j.hlc.2012.04.010

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  2 in total

Review 1.  LDL Apheresis and Lp (a) Apheresis: A Clinician's Perspective.

Authors:  Meral Kayikcioglu
Journal:  Curr Atheroscler Rep       Date:  2021-02-17       Impact factor: 5.113

2.  An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study".

Authors:  Jing Pang; Miao Hu; Jie Lin; Takashi Miida; Hapizah M Nawawi; Jeong Euy Park; Xue Wu; Anis S Ramli; Ngoc Thanh Kim; See Kwok; Lourdes E Gonzalez-Santos; Ta-Chen Su; Thanh Huong Truong; Handrean Soran; Shizuya Yamashita; Brian Tomlinson; Gerald F Watts
Journal:  BMJ Open       Date:  2017-10-25       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.